HomeFinancial MarketsKadmon Holdings Inc. (KDMN) stock declines during pre-market trading. Here’s the update:

Kadmon Holdings Inc. (KDMN) stock declines during pre-market trading. Here’s the update:

Kadmon Holdings Inc. (NASDAQ: KDMN) stock gained by 1.77% at last close however the KDMN stock-price plunge by 1.09% in the pre-market trading session. Kadmon is a biopharmaceutical business that develops, manufactures, and distributes novel treatments for unfulfilled medical needs.

>> 7 Top Picks for the Post-Pandemic Economy << 

KDMN stock, Current Update

REZUROCKTM (belumosudil) tablets have been included to the NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease, according to Kadmon Holdings (GVHD). REZUROCK is currently included as a recommended systemic treatment for steroid-refractory chronic GVHD in the NCCN Recommendations in the United States, with a Category 2A classification.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Read More

REZUROCK (belumosudil) 200 mg once daily (QD) was authorized by the US Food and Drug Administration on July 16, 2021, for the purpose of  treating  adult and pediatric patients 12 years and older with recurrent graft-versus-host disease (cGVHD) following failure of minimum two prior lines of systemic therapy.


REZUROCK was approved by the FDA due to the findings of ROCKstar (KD025-213) which is a randomized, open-label, multicenter pivotal study of REZUROCK in individuals with cGVHD who had two to five lines of systemic treatment. The NCCN recommendations state that “belumosudil is a potential treatment for steroid-refractory cGVHD that is well tolerated and yields clinically significant responses,” based on the ROCKstar trial.

The National Cancer Institute’s Cancer Centers Network is a non-profit organization comprised of 31 top cancer centers dedicated to patient safety, research, and education. NCCN is committed to developing and enabling cancer care that is effective, efficient, and accessible so that patients can live better lives.

>> 7 Top Picks for the Post-Pandemic Economy << 

Harlan W. Waksal, MD, President and CEO of KDMN Stock stated,

REZUROCK’s quick inclusion in NCCN recommendations following full FDA approval confirms the drug’s successful clinical effect in this tricky therapeutic environment. They are pleased for this significant milestone as they pursue their efforts to raise REZUROCK awareness among healthcare providers and patients with persistent GVHD.

Must Read

Related News


Please enter your comment!
Please enter your name here